← All forecasts · October 26–30

REGN / Q3 2026 (FQ3 2026 - Sep 2026; quarter ended 2026-09-30, fiscal year ends Dec-31)

Regeneron Pharmaceuticals, Inc.

Reported: Oct 30, 2026

Forecast published

Opus 5.5 High in Shortcut

Shortcut

16.47

Normalized diluted EPS

+1.7% vs Street

Off by $3.60 per share

Street

16.19

Normalized diluted EPS

October 25 consensus snapshot

Off by $3.88 per share

Real

20.07

Regeneron issuer non-GAAP diluted EPS

Shortcut win

Reported result · Oct 30 ↗ · The issuer Financial Highlights and reconciliation directly report Q3 non-GAAP diluted EPS 20.07 versus GAAP diluted 18.45.

USD per diluted common share. Comparisons use unrounded estimates.

Model download

Explore the assumptions and calculations behind the forecast.

Open in Shortcut ↗Download XLSX ↓

Shortcut’s reasoning.

Sanofi development balance fully repaid at 30-Jun-26 (10-Q 2Q26): 3Q26 Sanofi profit share is recorded without the ~$253m/qtr deduction; modeled at 36.3% of $6.31bn Dupixent+Kevzara sales (Dupixent +27% U.S./+22% ROW Y/Y).

EYLEA HD U.S. demand +13% Q/Q per management low-to-mid-teens guide, net price -2.5%; EYLEA U.S. -14% demand and -3% price with the Aug-26 Yesafili biosimilar launch.

Opex below the full-year guidance run-rate, consistent with FY25 landing at/below the low end: non-GAAP R&D $1,530m, SG&A $610m, COCM $245m; pre-announced acquired IPR&D $22m (8-K 6-Oct-26).

On the record.

Reporting period
Q3 2026 (FQ3 2026 - Sep 2026; quarter ended 2026-09-30, fiscal year ends Dec-31)
Reporting basis
Normalized = company non-GAAP net income per diluted common share, USD (Income Statement!G158 = G134/G157); GAAP diluted EPS in Income Statement!G67. Ordinary/common shares, no ADR, no split adjustment.
Consensus snapshot
October 25, 2026
Model / effort
Opus 5.5 · High effort
Workbook
Reviewed workbook
Record history
Forecast generated
Oct 27, 2026 at 5:07 PM PDT
Original author completed
Oct 27, 2026 at 6:36 AM PDT
Reviewed revision completed
Oct 27, 2026 at 5:07 PM PDT
First published
Oct 27, 2026 at 10:11 PM PDT
Result basis

The issuer Financial Highlights and reconciliation directly report Q3 non-GAAP diluted EPS 20.07 versus GAAP diluted 18.45. Non-GAAP net income 2150m and the published non-GAAP diluted common-share definition match the accepted convention. Prior-year non-GAAP diluted 11.83 matches frozenhistory. The announced Sanofi 1bn upfront is to be recognized in fourth-quarter 2026 collaboration revenue, not a new locally constructed Q3 adjustment. Original forecast, IPRD/SBC and share judgments remain fixed.